Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ensysce Biosciences, Inc. (ENSC)

0.7001   -0.069 (-9.01%) 01-27 16:00
Open: 0.7499 Pre. Close: 0.7694
High: 0.755 Low: 0.6911
Volume: 2,689,015 Market Cap: 4(M)

Technical analysis

as of: 2023-01-27 4:44:10 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.36     One year: 1.78
Support: Support1: 0.58    Support2: 0.49
Resistance: Resistance1: 1.17    Resistance2: 1.52
Pivot: 0.73
Moving Average: MA(5): 0.73     MA(20): 0.74
MA(100): 2.92     MA(250): 10.83
MACD: MACD(12,26): -0.2     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 13.2     %D(3): 14.5
RSI: RSI(14): 39.8
52-week: High: 35.59  Low: 0.45
Average Vol(K): 3-Month: 2,560 (K)  10-Days: 8,430 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ENSC ] has closed above bottom band by 35.6%. Bollinger Bands are 86.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.76 - 0.76 0.76 - 0.76
Low: 0.68 - 0.69 0.69 - 0.69
Close: 0.69 - 0.7 0.7 - 0.71

Company Description

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Headline News

Wed, 25 Jan 2023
Why Ensysce Biosciences Stock Is Exploding Higher During Wednesday's Session - Benzinga

Wed, 25 Jan 2023
Ensysce Biosciences (ENSC) Announces Initiation of Final Stage of ... - StreetInsider.com

Mon, 23 Jan 2023
2023-01-23 | NDAQ:ENSC | Press Release | Ensysce Biosciences Inc. - Stockhouse

Tue, 10 Jan 2023
Edinburgh skincare firm plans Japanese growth after trade mission - Insider.co.uk

Tue, 13 Dec 2022
Premarket Mover: Ensysce Biosciences Inc (ENSC) Up 3.88% - InvestorsObserver

Thu, 08 Dec 2022
Do Traders Think Ensysce Biosciences Inc (ENSC) Can Turn Around Thursday? - InvestorsObserver

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 6 (M)
Shares Float 2 (M)
% Held by Insiders 18.7 (%)
% Held by Institutions 19.6 (%)
Shares Short 143 (K)
Shares Short P.Month 138 (K)

Stock Financials

EPS -1.34
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.76
Profit Margin (%) 0
Operating Margin (%) -735
Return on Assets (ttm) -139.1
Return on Equity (ttm) 0
Qtrly Rev. Growth -76.7
Gross Profit (p.s.) -0.19
Sales Per Share 0.42
EBITDA (p.s.) -3.13
Qtrly Earnings Growth 0
Operating Cash Flow -18 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -0.53
PEG Ratio 0
Price to Book value -0.26
Price to Sales 1.64
Price to Cash Flow -0.25

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.